-1.18%
-0.68%
-7.99%
6.52%
24.17%
2.09%
-15.90%
AI Spotlight on BAVA
Company Description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers.
It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service.It operates in the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and internationally.Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Market Data
| Last Price | 197.55 |
| Change Percentage | -1.18% |
| Open | 201.4 |
| Previous Close | 199.9 |
| Market Cap ( Millions) | 15537 |
| Volume | 515840 |
| Year High | 300 |
| Year Low | 143.4 |
| M A 50 | 194.6 |
| M A 200 | 198.99 |
Financial Ratios
| FCF Yield | 1.80% |
| Dividend Yield | 0.00% |
| ROE | 10.75% |
| Debt / Equity | 1.07% |
| Net Debt / EBIDTA | -49.86% |
| Price To Book | 1.45 |
| Price Earnings Ratio | 13.83 |
| Price To FCF | 55.7 |
| Price To sales | 2.56 |
| EV / EBITDA | 8.28 |
News
- 10:50 - Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
- Jan -27 - Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
- Jan -20 - Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
- Jan -09 - Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
- Dec -17 - Bavarian Nordic signs mpox vax deal with Serum Institute of India
- Dec -16 - Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India
- Dec -13 - Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- Dec -13 - New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
- Dec -11 - Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program
- Nov -29 - Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- Nov -29 - Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Nov -16 - Bavarian Nordic AS (BVNKF) Q3 2024 Earnings Call Highlights: Strong Travel Health Growth and ...
- Nov -15 - Trump’s RFK Jr. Pick Weighs on Vaccine Makers
- Nov -15 - Bavarian Nordic shares sink by 12% after mpox sales slump in Q3
- Nov -15 - US expected to increase biodefence spending under Trump, says vaccine maker Bavarian Nordic
- Nov -15 - European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
- Nov -15 - Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
- Nov -07 - Bavarian Nordic’s mpox vaccine to be trialled in pregnant women and infants
- Oct -30 - Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?
- Oct -29 - Bavarian eyes Mpox vaccine label expansion to include toddlers, kickstarts Phase II trial
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Life-Saving Vaccines
Expected Growth : 9.95 %
What the company do ?
Bavarian Nordic A/S's life-saving vaccines protect against infectious diseases, including smallpox, Ebola, and rabies, providing critical immunization for public health crises.
Why we expect these perspectives ?
Bavarian Nordic A/S's life-saving vaccines segment growth is driven by increasing demand for immunization against infectious diseases, government investments in public health infrastructure, and the company's strong R&D pipeline, resulting in a 9.95% growth rate. Additionally, partnerships with global health organizations and expanding distribution channels in emerging markets contribute to the segment's rapid expansion.
Bavarian Nordic A/S Products
| Product Range | What is it ? |
|---|---|
| IMVANEX | A smallpox vaccine approved in Canada for active immunization against smallpox disease in persons 18 years of age and older. |
| IMVAMUNE | A smallpox vaccine approved in the European Union for active immunization against smallpox disease in persons 18 years of age and older. |
| MVA-BN | A vaccine candidate against COVID-19, currently in Phase 2 development. |
| BN-Polio | A vaccine candidate against polio, currently in preclinical development. |
| BN-RSV | A vaccine candidate against respiratory syncytial virus (RSV), currently in preclinical development. |
| BN-HBV | A vaccine candidate against hepatitis B, currently in preclinical development. |
Bavarian Nordic A/S's Porter Forces
Threat Of Substitutes
The threat of substitutes for Bavarian Nordic A/S is moderate due to the presence of alternative cancer treatments and vaccines. However, the company's focus on novel immunotherapies and vaccines may reduce the threat of substitutes.
Bargaining Power Of Customers
The bargaining power of customers is low for Bavarian Nordic A/S, as the company's products are primarily sold to healthcare providers and governments, which have limited negotiating power.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate for Bavarian Nordic A/S, as the company relies on a few key suppliers for raw materials and manufacturing services. However, the company's strong relationships with suppliers mitigate this risk.
Threat Of New Entrants
The threat of new entrants is high for Bavarian Nordic A/S, as the biotechnology industry is highly competitive and new companies are emerging with innovative technologies and products.
Intensity Of Rivalry
The intensity of rivalry is high for Bavarian Nordic A/S, as the company operates in a highly competitive industry with many established players and new entrants vying for market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.59% |
| Debt Cost | 10.40% |
| Equity Weight | 99.41% |
| Equity Cost | 10.58% |
| WACC | 10.58% |
| Leverage | 0.60% |
Bavarian Nordic A/S : Quality Control
Bavarian Nordic A/S passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CGEN | Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of … |
| MEDCL.PA | MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends … |
| GLPG.AS | Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that … |
| KURN.SW | Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. … |
| MDWD | MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
MedinCell
A-Score
1-Year Total Return ->
🥈
Kuros Biosciences
A-Score
1-Year Total Return ->
🥉
Galapagos
A-Score
1-Year Total Return ->
4
Bavarian Nordic
A-Score
1-Year Total Return ->
5
MediWound
A-Score
1-Year Total Return ->
6
